Wang Z, et al. - Researchers analyzed seven studies with 11,874 eligible patients, to assess the efficacy as well as the safety of prasugrel- or ticagrelor-based triple-antiplatelet treatments (TAPTs) vs that of clopidogrel TAPTs in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. These studies were identified from PubMed, Embase, and Cochrane’s Library, and included relevant randomized controlled trials about prasugrel or ticagrelor (test) vs clopidogrel (control). Based on the findings, it was concluded that a reduction in the rate of major adverse cardiovascular events, with no increase in bleeding, may be achieved with a prasugrel- or ticagrelor-based TAPT in this patient population.